What Miofilin Treats: Main Therapeutic Uses and Benefits

Miofilin (Aminophylline) is used to provide symptomatic relief across a narrow yet critical range of respiratory conditions. The medication supports patients by easing the muscle tension that causes airway constriction, helping with a more consistent breathing rhythm and reducing the overall burden of distressing symptoms.

It is commonly used across conditions characterized by periods of heightened symptoms, specifically acute asthma exacerbation, Chronic Obstructive Pulmonary Disease (COPD), and to assist in managing apnea of prematurity in infants. This medication is applied across domains where additional symptomatic support is needed, particularly during episodes of sudden symptom escalation.

Quick Fact: Relief for Acute Bronchospasm

Miofilin is considered relevant for easing symptoms related to physical discomfort and noticeable physiological strain caused by constricted airways. Its primary role is applied to provide supportive relief during a respiratory crisis or to manage the persistent airflow narrowing associated with chronic lung diseases.

Regulatory References

1. NIH MedlinePlus overview

Eligibility Map: Who can and cannot use Miofilin — Official Regulatory Information

The eligibility for Miofilin (Aminophylline) is strictly defined by regulatory authorities based on patient age, underlying health conditions, and sensitivity to the drug.

Eligibility Scope

Official Eligibility Statements

• Miofilin is contraindicated in any patient with a documented allergy to its components or in those currently receiving other xanthine-derivative medications.
• The drug is not recommended for infants under 6 months of age due to highly variable metabolism and unpredictable clearance.
• Patients with cardiac or hepatic dysfunction are subject to restricted use because these conditions significantly decrease the drug's elimination rate, increasing the risk of toxicity.

The regulatory profile is based on defining absolute prohibitions and conditional eligibility constraints determined by patient physiology and comorbidities, ensuring use is confined to populations where the risks associated with the drug's narrow therapeutic range can be managed.

Interactions with other medicines and products

Miofilin, which contains the active substance Aminophylline (Theophylline), has several officially documented interaction patterns based on regulatory labeling, primarily affecting the clearance and physiological effects of Theophylline.

Formal Prohibitions and Exposure Changes

Co-administration with other Xanthine Drugs (e.g., Theophylline or Pentoxifylline) is formally contraindicated due to the serious risk of additive toxicity. Interactions that increase plasma concentration of Theophylline involve substances like Cimetidine, Macrolide Antibiotics, and Quinolone Antibiotics (e.g., Ciprofloxacin), as these reduce clearance. Conversely, Rifampicin and certain Antiepileptics (e.g., Phenytoin) increase Theophylline clearance, resulting in a documented decrease in plasma concentrations.

Pharmacodynamic and Substance Interactions

Pharmacodynamic interactions include an increased risk of hypokalaemia when Miofilin is combined with Beta2-adrenergic agonists, corticosteroids, or diuretics. The drug also officially inhibits the effect of Adenosine receptor agonists. Concerning non-medicinal substances, Tobacco Smoking and the herbal product St John’s Wort are documented to increase Theophylline clearance and decrease circulating levels. Caffeine may contribute to additive central nervous system stimulant effects.

Population-Specific Considerations

Official regulatory documents note that elderly patients and those with hepatic disease have physiologically decreased clearance, making them more susceptible to adverse outcomes from exposure-modifying interactions.

The mechanism of action for Aminophylline primarily involves its activity as a non-selective inhibitor of Phosphodiesterase (PDE) enzymes, specifically PDE3 and PDE4. This inhibition blocks the degradation of the cellular messenger cyclic AMP ( cAMP), leading to its accumulation inside smooth muscle cells. The elevated cAMP levels initiate a cascade that reduces the concentration of intracellular calcium, resulting directly in the relaxation of bronchial smooth muscle and reduces the tension exerted by the bronchial smooth muscle tissue. A secondary mechanism is the non-selective antagonism of Adenosine Receptors ( A1 and A2 B). Blocking these receptors prevents adenosine from signaling, which limits the initiation of constrictive responses and affects signaling patterns characteristic of inflammatory pathways. Furthermore, the cAMP-mediated signaling extends to the skeletal muscle fibers of the diaphragm, promoting increased contractility and endurance capacity of the muscles responsible for generating respiratory effort.

Miofilin, which contains the active ingredient Aminophylline, is administered through distinct routes depending on the required use pattern. The intravenous (IV) route is utilized for acute intervention, while oral forms (tablets or syrup) are typically used for steady, ongoing administration. Rectal administration via suppositories is also a recognized route, though its absorption may be inconsistent.

Official Administration Regimens

The official IV regimen follows a specific, two-phase procedural structure. It begins with a Loading Dose of 6 mg/kg of the patient's lean body weight (L.B.W.), which must be infused slowly over 20 to 30 minutes at a rate not exceeding 25 mg/minute. This single dose is immediately followed by a continuous Maintenance Infusion, with the rate carefully calculated and often starting around 0.7 mg/kg/hour. The IV solution may be prepared by dilution with compatible fluids such as 5% Dextrose.

For oral use, the medication is typically administered in divided daily doses, such as every 6 to 8 hours. A crucial procedural instruction for proper use is that extended-release tablets must be swallowed whole and cannot be crushed or chewed.

Dose Adjustment and Monitoring

The administration protocol mandates that all doses be calculated based on L.B.W. to ensure proper systemic delivery. The maintenance rates require reduction for certain patient groups, including older adults and those with hepatic or cardiac impairment. Furthermore, the entire course of therapy, particularly during initiation and dosage changes, is structurally dependent on Therapeutic Drug Monitoring (TDM). This process involves measuring the serum concentration to guide necessary adjustments and maintain the level within the accepted therapeutic range, which defines the official pattern of use.

Research evidence / Overview of Studies for Miofilin

Evidence for Acute Asthma Exacerbation

Research was studied for use in individuals experiencing a sudden, severe worsening of asthma symptoms, known as an acute asthma exacerbation. Studies monitored various outcomes reflecting physiological strain, including changes in objective lung function measures (such as FEV1) and standardized Asthma Severity Scores. Studies reported measurements of short-term changes in these physiological markers. Research highlights that the outcomes measured during the study period often varied when the agent was added to the combination of modern, high-dose standard treatments. The evidence is limited regarding patterns observed regarding major resource-use markers, such as outcomes related to hospital utilization, including the overall length of stay or Intensive Care Unit (ICU) admission.

Evidence for Chronic Obstructive Pulmonary Disease (COPD)

Miofilin was studied for use in patients with COPD, particularly during periods of heightened symptom activity known as acute exacerbations. Studies focused on outcomes related to systemic or functional imbalance, specifically monitoring changes in lung function measurements and levels of gases in the blood ( PaCO2 and pH), alongside scores for shortness of breath (dyspnea). Research describes patterns related to changes in these physiological measures. The data show patterns related to outcomes reflecting episodic or acute changes were mixed. Evidence contributes to understanding symptom patterns but reports limited information related to consistent patterns for outcomes related to the total duration of hospital stay.

Evidence for Apnea of Prematurity

Research has explored whether Miofilin was associated with effects in preterm infants (neonates) who experience breathing pauses, a condition known as apnea of prematurity. This application was evaluated using Systematic Reviews and comparative Randomized Controlled Trials (RCTs). These studies monitored outcomes describing episodic or acute changes, focusing primarily on the frequency of apnea events and the infant's reliance on respiratory support. Studies monitored how outcomes evolved when comparing this agent against other established methylxanthine compounds. Few direct comparisons against a simple placebo exist in the most current research, and long-term effects are not fully established because research focusing on follow-up, particularly for neurodevelopmental outcomes, remains limited.

Research Gaps and Uncertainties

The evidence highlights what is known and what is still uncertain about the agent's clinical profile. Evidence quality varies across studies when assessing major outcomes, where the research has reported varying patterns of outcomes. Long-term effects are not fully established; there is limited information for long-term outcomes related to sustained changes in functional status or the prevention of future episodes. The results apply only to the populations studied, and comparative evidence is lacking in some current scenarios.

Key Studies & References

1. Aminophylline Drug Information (FDA/DailyMed Monograph)

Common questions about Miofilin (FAQ)

Q: How is Miofilin different from [similar common drug name]?

Miofilin's active component is Aminophylline, which is a compound created by combining the base drug Theophylline with Ethylenediamine. Official documents state this chemical combination is used to increase the solubility and stability of the Theophylline, making it a preferred formulation for systemic delivery.

Q: Why do some people say Miofilin is not safe for heart issues?

Regulatory information indicates that Miofilin can affect the heart, as common side effects include tachycardia (fast heart rate) and palpitations. Additionally, official prescribing information indicates caution is required for patients who already have heart conditions, such as Congestive Heart Failure, because these conditions can reduce how quickly the body clears the drug, increasing the risk of adverse effects.

Q: Can I take Miofilin while I'm also taking vitamins or herbal supplements?

Official documents note that the herbal product St John’s Wort and substances like caffeine can affect the way the body processes the drug. The drug's clearance profile means that all other medicines, vitamins, and supplements are relevant considerations when treatment is determined by a healthcare professional.

Q: Does Miofilin affect performance on driving or operating machinery?

The drug is associated with common nervous system effects such as headache, tremor, restlessness, and insomnia. Due to these effects, caution is advised when engaging in activities that require mental alertness, such as driving or operating machinery.

Q: Does Miofilin treat the underlying cause or just the symptoms?

Miofilin is classified as a bronchodilator, and its primary documented purpose is to relieve acute symptoms. The medication achieves this by working directly to relax the smooth muscles in the airways, which improves air flow and reduces the physical tension of bronchospasm.

Q: Is a headache a common side effect when starting Miofilin?

Headache is officially classified as a Common adverse reaction. Official information indicates that these common effects, which can be similar to the effects of caffeine, are often transient and may be observed especially as the body reaches the necessary therapeutic levels.

Q: If I stop taking Miofilin, how long does it stay in my system?

The time the active component (theophylline) stays in the system varies greatly, but the half-life is described in regulatory documents. In healthy, non-smoking adults, the half-life is typically stated as 7 to 9 hours, but it can be shorter in children or longer in older adults or those with certain medical conditions.

Q: Can Miofilin affect fertility or planning a pregnancy?

Studies in animal models have indicated a documented impairment of fertility when the drug was administered at high doses. The drug is known to cross the placenta in humans, and its use during pregnancy is considered appropriate only when the clinical benefit is determined to outweigh the documented risks.

Q: Do you need lab tests or blood work before starting Miofilin?

The treatment protocol is structurally dependent on Therapeutic Drug Monitoring (TDM). This process requires measuring the drug’s concentration in the blood, which may be needed when treatment is first initiated to guide necessary adjustments and maintain the level within the accepted therapeutic range.

Q: Is it true that Miofilin can affect blood pressure readings?

Official documents note that the drug can affect the cardiovascular system. Cases have been documented where the administration of Aminophylline can lead to a decrease in blood pressure. For this reason, caution is required for use in patients with pre-existing conditions like hypertension.

Q: Why is Miofilin sometimes given with another medicine?

The medication is often officially used as an adjunct, meaning it is a supplementary treatment alongside standard therapies. For acute exacerbations, it is documented to be used alongside inhaled beta2-adrenergic agonists and systemic corticosteroids.

Q: Is there a generic version of Miofilin available?

Official reports indicate that the oral dosage forms of the active ingredient (Aminophylline) have been discontinued in some regions, and there is no generic version available for these forms. However, the solution for injection remains available for use in hospital settings.

Q: Are there any known issues with Miofilin and sunlight exposure?

Official safety data sheets and storage guidelines state that the drug should be protected from light and stored away from direct sunlight. Regulatory guidelines specify protection from light and sun is necessary for the drug’s physical storage requirements.

Q: Is there a link between Miofilin and liver damage?

Regulatory documentation states that patients with hepatic impairment (liver disease) are subject to restricted use and careful monitoring. This is because reduced drug processing significantly increases the risk of serious adverse reactions and toxicity.

Q: What temperature should I store Miofilin at?

The medication must be stored at a controlled room temperature, typically defined by regulatory bodies as a range between 20° to 25°C (68° to 77°F). The drug is to be kept in its original container, protected from light and moisture, as part of the official storage conditions.

Q: How often do the side effects of Miofilin typically occur?

Side effects are officially classified by their frequency in regulatory documents. For example, nervous system issues like headache, tremor, and insomnia, along with digestive upset like nausea, are classified as Common adverse reactions, while severe reactions are classified as Rare.

Q: What is the risk of overdose with Miofilin?

The active component has a narrow therapeutic index, meaning there is only a small difference between the effective concentration and a toxic concentration in the blood. Regulatory warnings note this narrow margin of safety and caution that overdosage can lead to life-threatening issues, such as seizures or severe cardiac arrhythmias.

How to Store and Dispose of Miofilin (Aminophylline)

Official regulatory guidelines for storing Miofilin emphasize maintaining chemical stability and safety. The medicine must be stored in its original, tightly closed container and kept out of the sight and reach of children.

Storage Requirements

Disposal Instructions

To prevent environmental contamination, do not dispose of unused or expired Miofilin by pouring it down a drain or placing it in household trash. Return the medicine to a pharmacy or government-designated collection program for proper pharmaceutical waste disposal, following local regulations.